Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.

Olivier RascolValérie Cochen De CockAnne Pavy-Le TraonAlexandra Foubert-SamierClaire ThalamasAgnes SommetVanessa RousseauSantiago Perez LloretMargherita FabbriJean Philippe AzulayJean-Christophe CorvolPhilippe CouratierPhilippe DamierLuc DefebvreFranck DurifChristian GenyJean-Luc HouetoPhilippe RemyChristine TranchantMarc VerinFrançois TisonWassillios G Meissnernull null

Published in: Movement disorders : official journal of the Movement Disorder Society (2021)

The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. © 2021 International Parkinson and Movement Disorder Society.

Keyphrases

phase iii
clinical trial
study protocol
phase ii
type diabetes
randomized controlled trial
double blind
combination therapy
skeletal muscle